| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Cancer Research UK Clinical Centre [M. A. R., P. C., N. P. M., P. J. S., R. E. B.] and Department of Urology [A. P.], St. James’s University Hospital, Leeds LS9 7TF, and School of Computing, University of Leeds, Leeds LS2 9JT [J. N.], United Kingdom
Recent advances in proteomic profiling technologies, such as surface enhanced laser desorption ionization mass spectrometry, have allowed preliminary profiling and identification of tumor markers in biological fluids in several cancer types and establishment of clinically useful diagnostic computational models. There are currently no routinely used circulating tumor markers for renal cancer, which is often detected incidentally and is frequently advanced at the time of presentation with over half of patients having local or distant tumor spread. We have investigated the clinical utility of surface enhanced laser desorption ionization profiling of urine samples in conjunction with neural-network analysis to either detect renal cancer or to identify proteins of potential use as markers, using samples from a total of 218 individuals, and examined critical technical factors affecting the potential utility of this approach.
Samples from patients before undergoing nephrectomy for clear cell renal cell carcinoma (RCC; n = 48), normal volunteers (n = 38), and outpatients attending with benign diseases of the urogenital tract (n = 20) were used to successfully train neural-network models based on either presence/absence of peaks or peak intensity values, resulting in sensitivity and specificity values of 98.3–100%. Using an initial "blind" group of samples from 12 patients with RCC, 11 healthy controls, and 9 patients with benign diseases to test the models, sensitivities and specificities of 81.8–83.3% were achieved. The robustness of the approach was subsequently evaluated with a group of 80 samples analyzed "blind" 10 months later, (36 patients with RCC, 31 healthy volunteers, and 13 patients with benign urological conditions). However, sensitivities and specificities declined markedly, ranging from 41.0% to 76.6%. Possible contributing factors including sample stability, changing laser performance, and chip variability were examined, which may be important for the long-term robustness of such approaches, and this study highlights the need for rigorous evaluation of such factors in future studies.
This article has been cited by other articles:
|
|
 |
|
  P. de Valpine, H.-M. Bitter, M. P. S. Brown, and J. Heller A simulation-approximation approach to sample size planning for high-dimensional classification studies Biostat., July 1, 2009; 10(3): 424 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Lancashire, C. Lemetre, and G. R. Ball An introduction to artificial neural networks in bioinformatics--application to complex microarray and mass spectrometry datasets in cancer studies Brief Bioinform, May 1, 2009; 10(3): 315 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Magistroni, G. Ligabue, V. Lupo, L. Furci, M. Leonelli, L. Manganelli, M. Masellis, V. Gatti, F. Cavazzini, W. Tizzanini, et al. Proteomic analysis of urine from proteinuric patients shows a proteolitic activity directed against albumin Nephrol. Dial. Transplant., May 1, 2009; 24(5): 1672 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Decramer, A. G. de Peredo, B. Breuil, H. Mischak, B. Monsarrat, J.-L. Bascands, and J. P. Schanstra Urine in Clinical Proteomics Mol. Cell. Proteomics, October 1, 2008; 7(10): 1850 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hilario and A. Kalousis Approaches to dimensionality reduction in proteomic biomarker studies Brief Bioinform, March 1, 2008; 9(2): 102 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Seam, D. A. Gonzales, S. J. Kern, G. L. Hortin, G. T. Hoehn, and A. F. Suffredini Quality Control of Serum Albumin Depletion for Proteomic Analysis Clin. Chem., November 1, 2007; 53(11): 1915 - 1920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. A. Vanhoutte, C. Laarakkers, E. Marchiori, P. Pickkers, J. F. M. Wetzels, J. L. Willems, L. P. van den Heuvel, F. G. M. Russel, and R. Masereeuw Biomarker discovery with SELDI-TOF MS in human urine associated with early renal injury: evaluation with computational analytical tools Nephrol. Dial. Transplant., October 1, 2007; 22(10): 2932 - 2943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Goligorsky, F. Addabbo, and E. O'Riordan Diagnostic Potential of Urine Proteome: A Broken Mirror of Renal Diseases J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2233 - 2239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Muller, C. A. Muller, and H. Dihazi Clinical proteomics--on the long way from bench to bedside? Nephrol. Dial. Transplant., May 1, 2007; 22(5): 1297 - 1300. [Full Text] [PDF]
|
|
|
|
|
|
J. Albrethsen Reproducibility in Protein Profiling by MALDI-TOF Mass Spectrometry Clin. Chem., May 1, 2007; 53(5): 852 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Fiedler, S. Baumann, A. Leichtle, A. Oltmann, J. Kase, J. Thiery, and U. Ceglarek Standardized Peptidome Profiling of Human Urine by Magnetic Bead Separation and Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Clin. Chem., March 1, 2007; 53(3): 421 - 428. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mosley, F. W. K. Tam, R. J. Edwards, J. Crozier, C. D. Pusey, and L. Lightstone Urinary proteomic profiles distinguish between active and inactive lupus nephritis Rheumatology, December 1, 2006; 45(12): 1497 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Jahnukainen, D. Malehorn, M. Sun, J. Lyons-Weiler, W. Bigbee, G. Gupta, R. Shapiro, P. S. Randhawa, R. Pelikan, M. Hauskrecht, et al. Proteomic Analysis of Urine in Kidney Transplant Patients with BK Virus Nephropathy J. Am. Soc. Nephrol., November 1, 2006; 17(11): 3248 - 3256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Pisitkun, R. Johnstone, and M. A. Knepper Discovery of Urinary Biomarkers Mol. Cell. Proteomics, October 1, 2006; 5(10): 1760 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-J. Cheng, L.-C. Chen, K.-Y. Chien, Y.-J. Chen, J. T.-C. Chang, H.-M. Wang, C.-T. Liao, and I-H. Chen Oral Cancer Plasma Tumor Marker Identified with Bead-Based Affinity-Fractionated Proteomic Technology Clin. Chem., December 1, 2005; 51(12): 2236 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Dekker, W. Boogerd, G. Stockhammer, J. C. Dalebout, I. Siccama, P. Zheng, J. M. Bonfrer, J. J. Verschuuren, G. Jenster, M. M. Verbeek, et al. MALDI-TOF Mass Spectrometry Analysis of Cerebrospinal Fluid Tryptic Peptide Profiles to Diagnose Leptomeningeal Metastases in Patients with Breast Cancer Mol. Cell. Proteomics, September 1, 2005; 4(9): 1341 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Banks, A. J. Stanley, D. A. Cairns, J. H. Barrett, P. Clarke, D. Thompson, and P. J. Selby Influences of Blood Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry Clin. Chem., September 1, 2005; 51(9): 1637 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. Baggerly, J. S. Morris, S. R. Edmonson, and K. R. Coombes Signal in Noise: Evaluating Reported Reproducibility of Serum Proteomic Tests for Ovarian Cancer J Natl Cancer Inst, February 16, 2005; 97(4): 307 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Diamandis and D.-E. van der Merwe Plasma Protein Profiling by Mass Spectrometry for Cancer Diagnosis: Opportunities and Limitations Clin. Cancer Res., February 1, 2005; 11(3): 963 - 965. [Full Text] [PDF]
|
|
|
|
|
|
K. R. Coombes Analysis of Mass Spectrometry Profiles of the Serum Proteome Clin. Chem., January 1, 2005; 51(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
|
|
S. Skates and O. Iliopoulos Molecular Markers for Early Detection of Renal Carcinoma: Investigative Approach Clin. Cancer Res., September 15, 2004; 10(18): 6296S - 6301S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vlahou, A. Giannopoulos, B. W. Gregory, T. Manousakas, F. I. Kondylis, L. L. Wilson, P. F. Schellhammer, G. L. Wright Jr, and O. J. Semmes Protein Profiling in Urine for the Diagnosis of Bladder Cancer Clin. Chem., August 1, 2004; 50(8): 1438 - 1441. [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool: Opportunities and Potential Limitations Mol. Cell. Proteomics, April 1, 2004; 3(4): 367 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis Analysis of Serum Proteomic Patterns for Early Cancer Diagnosis: Drawing Attention to Potential Problems J Natl Cancer Inst, March 3, 2004; 96(5): 353 - 356. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
